B. Van Baelen - Concepedia

Author

B. Van Baelen

Janssen (Belgium)

Also Known As

B Van Baelen, B van Baelen, B. Baelen, B. Van Baelen, B. van Baelen, Bart Van Baelen, Bart van Baelen

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Janssen (Germany)Witten/Herdecke University University of Zurich University of British Columbia

About

B. Van Baelen is an author at Janssen (Belgium) specializing in medicine, neurology, and treatment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	302
2	Neurology	4	4	249
3	Health Sciences	1	1	29
4	Geriatrics	1	1	39
5	Hepatology	1	1	53

B. Van Baelen

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Prolactin Levels and Adverse Events in Patients Treated with Risperidone David L. Kleinberg, John M. Davis, R. De Coster, Journal of Clinical Psychopharmacology	1999	306
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial Alistair Burns, Roberto Bernabei, Roger Bullock, The Lancet Neurology Neurodegenerative DiseasesSevere AlzheimerAlzheimer's DiseaseMedicineDouble-blind Trial	2008	150
Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease Howard Feldman, B. Van Baelen, Shane M. Kavanagh, Alzheimer Disease & Associated Disorders	2005	103
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease Howard Feldman, Tuula Pirttilä, Jean François Dartigues, International Journal of Geriatric Psychiatry	2008	66
The effects of galantamine treatment on caregiver time in Alzheimer's disease Mary Sano, Gordon Wilcock, B. Van Baelen, International Journal of Geriatric Psychiatry	2003	63
Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months Rafael Blesa, Michael Davidson, Alexander Kurz, Dementia and Geriatric Cognitive Disorders	2003	57
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY Stefan Zeuzem, Sulkowski, Fabien Zoulim, Interim AnalysisHepatologyHepatitis CThe Extend StudyViral Hepatitis	2010	53
Effects of ritonavir‐boosted darunavir <i>vs</i>. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers F Tomaka, Éric Lefebvre, V. Sekar, HIV Medicine	2009	44
Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months. David Wilkinson, C. Hock, Martin R. Farlow, PubMed AgingNeurochemical BiomarkersAlzheimer's DiseaseNeurologyAging-associated Disease	2002	39
Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimerʼs Disease Stephen M. Aronson, B. Van Baelen, Shane Kavanagh, Drugs & Aging Neurodegenerative DiseasesAlzheimer's DiseaseMedicineOptimal DosingNeurochemical Biomarkers	2009	31

Page 1